Literature DB >> 11570945

Recurrent pneumococcal bacteremia: risk factors and outcomes.

G S Turett1, S Blum, E E Telzak.   

Abstract

BACKGROUND: Recurrent pneumococcal bacteremia receives infrequent mention in the literature, usually in association with patients who are immunocompromised.
OBJECTIVE: To examine recurrent cases of pneumococcal bacteremia to determine risk factors and outcomes (mortality rates and emergence of resistance) associated with recurrences.
METHODS: We retrospectively reviewed all cases of pneumococcal bacteremia identified by our microbiology laboratory from January 1, 1992, through December 31, 1996. Demographic, clinical, and laboratory data were abstracted.
RESULTS: There were 462 bacteremic episodes in 432 patients; 23 of these patients had 30 recurrent episodes. The 5.3% recurrence rate (23/432) is greater than that previously described. The median time to recurrence was 200 days. The mean age of patients with recurrences was 34 years, 70% were women, all were black or Hispanic (in near equal numbers), and 87% were infected with the human immunodeficiency virus (HIV). Human immunodeficiency virus infection, coexistent cancer, and female sex were independent predictors of recurrence. Only patients who were HIV-infected had multiple recurrences. Isolates from recurrent bacteremias were more likely to be penicillin-resistant than were initial bacteremic isolates (relative risk, 2.0; P =.16). Patients with recurrences had a higher (although not statistically significant) mortality rate than those without recurrences (22% vs 16%; P =.33). There was an inverse relationship between severity of illness and likelihood of recurrence.
CONCLUSIONS: Rates of recurrent pneumococcal bacteremia may be higher than previously reported. In patients with recurrent pneumococcal bacteremia, the presence of an underlying immunodeficiency should be investigated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11570945     DOI: 10.1001/archinte.161.17.2141

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  7 in total

1.  IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease.

Authors:  Cheng-Lung Ku; Capucine Picard; Melinda Erdös; Axel Jeurissen; Jacinta Bustamante; Anne Puel; Horst von Bernuth; Orchidée Filipe-Santos; Huey-Hsuan Chang; Tatiana Lawrence; Marc Raes; László Maródi; Xavier Bossuyt; Jean-Laurent Casanova
Journal:  J Med Genet       Date:  2006-09-01       Impact factor: 6.318

2.  Epidemiology of invasive pneumococcal disease and vaccine provision in a tertiary referral center.

Authors:  C Rock; C Sadlier; J Fitzgerald; M Kelleher; C Dowling; S Kelly; C Bergin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-03-24       Impact factor: 3.267

3.  How many episodes of hospital care might be prevented by widespread uptake of pneumococcal conjugate vaccine?

Authors:  E D G McIntosh
Journal:  Arch Dis Child       Date:  2003-10       Impact factor: 3.791

Review 4.  Clinical review: Respiratory failure in HIV-infected patients--a changing picture.

Authors:  Putul Sarkar; Husham F Rasheed
Journal:  Crit Care       Date:  2013-06-14       Impact factor: 9.097

5.  COMMUNITY ACQUIRED PNEUMOCOCCAL PNEUMONIA IN NORTHWESTERN NIGERIA: EPIDEMIOLOGY, ANTIMICROBIAL RESISTANCE AND OUTCOME.

Authors:  Garba Iliyasu; Farouq Dayyab Mohammad; Abdulrazaq Garba Habib
Journal:  Afr J Infect Dis       Date:  2017-11-15

6.  Missed Opportunities? A Retrospective Study Into Adults Hospitalized With Invasive Infection From Airway Pathogens.

Authors:  Emma L Smith; Bryan Tan; Alysia Bastas; Despina Kotsanas; Claire Dendle; Samar Ojaimi
Journal:  Open Forum Infect Dis       Date:  2022-07-05       Impact factor: 4.423

7.  Population-based surveillance for invasive pneumococcal disease in homeless adults in Toronto.

Authors:  Agron Plevneshi; Tomislav Svoboda; Irene Armstrong; Gregory J Tyrrell; Anna Miranda; Karen Green; Donald Low; Allison McGeer
Journal:  PLoS One       Date:  2009-09-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.